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(EBRT) (50.4 Gy±10 Gy boost to primary tumor and/or to 
positive lymph nodes, ratio of 3D-CRT/IMRT: 105/28 pts) with 
concurrent cisplatin followed by 25-35 Gy of PDR IGABT in 30-
50 pulses. Combined intracavitary+interstitial (IC/S) 
technique was used in 6/133 cases. Dose–volume parameters 
of HR-CTV, IRCTV and D2cc OARs (organs at risk) were 
determined and converted into biologically equivalent doses 
in 2 Gy fractions (EQD2). Clinical outcome parameters (local 
control (LC), cancer specific survival (CCS) and overall 
survival (OS), progression free survival (PFS)) were analysed 
actuarially and Gr. 3-4 late morbidity crude rates were 
scored using CTCAEv3.0.  
Results: Mean follow-up was 36 months (range, 4–90). The 
mean D90 and D98 for HR-CTV was 82.7±12.3 Gy and 75±7.5 
Gy, while for IR-CTV was 68.7±4.2 Gy and 64.1±4.3 
respectively. The mean D2cc for OARs was the following: 
bladder: 78.2±10.3 Gy, rectum: 65.8±7.2 Gy, sigmoid: 
62.9±7.6 Gy and intestine: 63.3±9 Gy. Complete remission 
was achieved in 129/133 patients (97%). Three year LC, CSS 
and OS were: 90%, 79%, and 75%. The 3-year in-field regional- 
and distant control were 85% and 72%. Node negative 
patients had significantly higher 3-year PFS (92 vs. 60%, p= 
0.0005) and OS (86 vs. 60%, p= 0.002) compared to node 
positive ones. Late Gr. 3-4 morbidity was the following 
(events/pts): GI (fistula, obstruction, proctitis): 9 (6.7%)/6, 
GU (cystitis, haematuria, fistula): 7 (5.2%)/5, vaginal 
stenosis: 9 (6.8%)/9. 
Conclusions: The clinical outcome obtained in this large 
Belgian retrospective series along with the published 
literature support image-guided BT and radio-(chemo)therapy 
as optimal therapeutic approach for patients suffering LACC.  
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OC-0132   
Biochemical failure in low and intermediate risk prostate 
cancer patients after LDR Brachytherapy appear similar 
A. Taggar1, K. Martell1, M. Sia1, S. Angyalfi1, S. Husain1 
1Tom Baker Cancer Centre, Radiation Oncology, Calgary, 
Canada  
 
Purpose/Objective: To determine if the outcome on patients 
who present with low risk (PSA ≤ 10, Gleason Score (GS) ≤ 6 
and Clinical Stage (CS) ≤ T2a) or low intermediate risk (PSA 
between 10 - 20 and a GS ≤ 6 and CS ≤ T2c or GS =7 and PSA ≤ 
10 and CS ≤ T2c) prostate cancer and receive treatment with 
a single modality therapy of LDR intra-operatively planned 
prostate brachytherapy have similar outcomes. 
Materials and Methods: All patients were treated with the 
intra-operative planning system SPOT (R) with real time 
contouring, planning and an automated seed delivery system. 
Prescribed dose was 144Gy to the prostate and a margin (2-
5mm). Data was prospectively collected on all patients. 829 
patients with low-risk (517) and intermediate-risk (312) 
prostate cancer, defined by risk stratification as above, were 
implanted during this 10-year period between May 2003 and 
December 2013. All patients were followed at our institution 
by the treating physician with PSA measured at every 3 
months for first 2 years, then every 6 months for 3 years and 
yearly thereafter. 
Results: Median (range) follow-up for entire cohort was 4.4 
years (3 months – 10.6 years). Median age at diagnosis was 
63.1 years (95% CI 62.3 – 63.9). Mean PSA at diagnosis was 6.3 
(95% CI 6.2 – 6.5) and mean gland size was 36.7 cc (95% CI 
35.9 – 37.4). 93.3% of patients had CS ≤ T2a, 3.4% had CS ≥ 
T2b, and CS was unknown for 3.3% patients. 102 (12.3%) 
patients were given pre-operative hormone suppression, to 
downsize gland size. 11 (1.33%) patients had biochemical 
failure (BF), defined by nadir+2. Observed median time to BF 
was 4.4 years (1.0 – 8.9 years). 31 patients died within the 
follow-up period with 5 year overall survival was 98.4% (SE 
+/- 0.5%). Only 1/31 patient had BF and died of prostate 
cancer. 5 year biochemical progression free survival was 
98.6% (SE +/-0.5%). 10 patients with BF were from low-risk 
group, whereas only one patient from intermediate-risk 
group had BF. There was no statistical difference in failure 
between low-risk and intermediate-risk patients, log-rank 
P=0.395. Others factors including age at diagnosis (p=0.859), 
PSA (p=0.856), clinical stage (p=0.885), gland volume at the 
time of implant (0.219), hormones suppression prior to the 
implant (0.098) and dosimetric parameters [D90 (p=0.977), 
V150 (p=0.421) and V200 (p=0.211)] were not statistically 
significant in predicting BF. We attempted to fit these factors 
in a logistic regression model, however, none reached 
significance for association with BF. 
Conclusions: This is one of the largest series to report on 
outcomes of low dose rate brachytherapy performed using 
intra-operative planning. We report excellent clinical 
outcomes with a low rate of biochemical failure in both low 
and intermediate-risk patients  
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Purpose/Objective: Improved ultrasound image quality 
makes it possible to make a reliable reconstruction of the I-
125 seed implant and prostate contours at the end of the 
implantation procedure at the OR. The purpose of this study 
was to evaluate if the dose distribution based on these 
reconstructions is a reasonable estimate for the actual 
distributed dose. Combined CT and MR imaging made 1 
month after seed implantation was considered to be the 
golden standard for the determination of the actual 
distributed dose. 
Materials and Methods: Of 15 consecutive patients a trans-
rectal ultrasound scan was made at the end of the procedure 
at the OR (TRUS-d0). Type STM1251 I-125 seeds with a source 
strength of 0.57-0.60 µGy.h-1.m2 were used. Seeds and 
spacers of various lengths were assembled in strands (Prolink, 
Bard Brachytherapy). After 1 month a CT and a T2-weighted 
MRI scan were made of these patients (CT/MR-1m). The seed 
reconstruction was based on the CT images, the prostate 
contours on the MR images, and the dose distribution on the 
fusion of both scans. The prostate volume (Vp), V100, V200 and 
D90 were determined from both TRUS-d0 and CT/MR-1m. 
Motion of the seeds was evaluated by comparing the position 
of individual seeds with respect to the centre of mass of the 
delineated prostate (COMp). 
Results: The average ratio ±1SD of Vp, V100, V200 and D90 based 
on CT/MR-1m versus TRUS-d0 were 0.82±0.07, 0.97±0.05, 
1.51±0.28 and 0.97±0.14 respectively. Despite some large 
individual differences in V100 and D90 between both methods, 
the average values were not significantly different (p>0.05). 
Differences in Vp and V200 were, however, highly significant 
(p<0.001) between both methods. The ratio of the methods 
for the 'volume' of the implant (= average distance cubed of 
COMp to the seeds) was 0.85±0.09 (p<0.001). There was a 
significant caudal displacement of 2.9±2.7mm of the seeds in 
the CT/MR-1m compared to TRUS-d0 method (p=0.001). 
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However, this displacement was larger for ventral seeds 
compared to dorsal seeds (see Fig. 1): 4.4±3.1mm versus 
1.7±2.6mm (p<0.001). Of the ventral seeds, cranial seeds 
showed larger displacements than caudal seeds: 5.3±3.1mm 
versus 3.5±3.1mm (p<0.001). 
 
 
Conclusions: Due to prostate volume changes and seed 
displacements after the seed implantation, a reliable 
quantitative assessment of dose-volume parameters for the 
prostate cannot be made at the end of the implantation 
procedure at the OR. A qualitative determination of possible 
cold spots, however, can be made if a potential displacement 
of ventral seed strands in caudal direction is considered.  
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Purpose/Objective: For low (LR)- and intermediate-risk (IR) 
prostate cancer, I-125 seed implant is a highly successful 
treatment modality. However, a small proportion of patients 
show tumor recurrence at some point. Salvage options 
depend on the location of tumor progression. With multi-
parametric MRI and Choline PET, patterns of failure can be 
established. The purpose of this study was therefore to 
identify the location and timing of tumor progression after 
brachytherapy.  
Materials and Methods: Between January 2003 and January 
2011, 328 patients with Gleason ≤7, PSA <20, clinical stage 
T1-T2 and a maximum prostate volume of 60 cc, were 
implanted with I-125 seeds (145 Gy). Date of progression was 
scored at either increase of PSA >2 µg/L above nadir, or 
established recurrence by biopsy and/or imaging, whichever 
was first. A PSA bounce (>2 µg/L increase) with spontaneous 
recovery was not scored as progression. Diagnostic 
procedures (including bone scan, multi-parametric MRI, 
Choline/PET CT, biopsies) were performed in most cases as a 
part of routine follow-up after rising PSA levels, determining 
the location(s) of first relapse. Cumulative incidences were 
estimated using Kaplan-Meier analysis. 
Results: 
 
At a median follow-up of 4.9 years (range 0.3 – 10.4), 5-year 
freedom from failure was 92 % for LR (n=214) and 88 % for IR 
(n=114). Six patients showed a PSA bounce>2 µg/L increase. 
Tumor Relapse was scored in 30 patients; in 4 cases follow-up 
imaging was lacking due to severe comorbidity or a wait and 
see policy. The first relapse location(s) are summarized in Fig 
1 (n=26). Local failure within the gland as (part of) a first 
event occurred in 46 % of the identified failures (12/26) with 
an estimated cumulative 5y incidence of 3.9 % in LR and 3.5 
% in IR patients (Log Rank p=0.8). Local failure in the 
prostate only (all pathology confirmed) occurred in 7 cases 
after a median follow-up of 4.3y (range 1.5 – 7.0) and a 
median PSA nadir of 0.6 µg/L; in 5 cases salvage 
prostatectomy was performed afterwards. Increased uptake 
in the seminal vesicles on follow-up Choline/PET CT (n=6) 
was observed 2 to 6y post-implantation (n=1 pathology 
confirmed). Patients who were diagnosed with distant failure 
as first site (n=5) had early relapses within 2 years and a high 
nadir (1.9 – 13.9 µg/L). Cumulative 5y incidence of failures 
occurring completely outside the gland (n=14) was 3.5 % for 
LR and 6.2 % for IR patients, which was a non-significant 
difference (p=0.15). 
Conclusions: Using multi-parametric MRI and Choline/PET 
CT, patterns of failure after brachytherapy were identified. 
Options for salvage treatment could be adapted accordingly, 
improving patient care. For solitary recurrences a local 
salvage treatment, such as prostatectomy, may be effective. 
The cases of early tumor progression completely outside the 
prostate gland, suggest that pre-treatment screening with 
MRI may improve patient selection and outcome for 
brachytherapy.  
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Purpose/Objective: To demonstrate the application of a 
biologically based inverse optimization algorithm for low dose 
rate (LDR) prostate focal brachytherapy treatment planning.  
